Fluicell

Fluicell EBIT Growth

The Year-over-Year EBIT Growth of Fluicell (FLUI.ST) as of Nov 20, 2026 is 45.18 %. In the previous year, Year-over-Year EBIT Growth was 41.06 % — a change of 10.02% (higher).

EBIT Growth

45.18 %

YoY

10.02%

Last updated:

Year-over-Year EBIT Growth of Fluicell is 2025 45.18 % . Year-over-Year EBIT Growth of Fluicell was 2024 41.06 % . It decreases by 10.02% higher compared to the previous year.

The Fluicell EBIT Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT Growth
Date
EBIT Growth
Jan 1, 2018
-98.74 SEK
Jan 1, 2019
-26.42 SEK
Jan 1, 2020
8.87 SEK
Jan 1, 2021
-27.42 SEK
Jan 1, 2022
-0.15 SEK
Jan 1, 2023
-23.71 SEK
Jan 1, 2024
41.06 SEK
Jan 1, 2025
45.18 SEK
The Fluicell EBIT Growth history
YEAREBIT GrowthYoY
45.18 %+10.02%
41.06 %-273.17%
-23.71 %+15,976.29%
-0.15 %-99.46%
-27.42 %-409.20%
8.87 %-133.56%
-26.42 %-73.24%
-98.74 %+98.51%
-49.74 %+71.40%
-29.02 %-78.53%
-135.16 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Fluicell Stock analysis

What does Fluicell do? Fluicell AB commercializes research tools BioPen and Dynaflow Resolve for studying, processing, and measuring drug impact on individual cells in cell-based pharmacology research. The company also develops bioprinting technology Biopixlar Retina, offering 2D and 3D options to create complex tissue-like structures with precise cell positioning control. These products target drug development research segments where individual cell analysis is critical. The primary buyers are pharmaceutical companies and research institutions focused on cell-based pharmacology. Fluicell AB's product portfolio includes BioPen, Dynaflow Resolve, and Biopixlar Retina, all designed for cell-based pharmacology research applications. The company's tools enable detailed analysis of drug effects at the single-cell level, supporting pharmaceutical research and development processes. Biopixlar Retina specifically addresses tissue engineering needs by allowing controlled creation of tissue-like structures in both 2D and 3D formats. The company's revenue streams come from selling these research tools and bioprinting technologies to pharmaceutical companies and research institutions. These segments value the precision and control offered by Fluicell's products for cell-based drug development studies. The products are positioned as essential tools for advanced cell analysis in pharmacology research environments. Fluicell is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Fluicell stock

Year-over-Year EBIT Growth of Fluicell is 45.18 % in 2025.

On Eulerpool you can find the complete historical development of Year-over-Year EBIT Growth Fluicell since 2006 – with annual values, charts, and detailed analysis.

EBIT growth measures the percentage change in operating earnings. It shows whether a company's core operations are becoming more profitable.

To evaluate Year-over-Year EBIT Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year EBIT Growth.

Year-over-Year EBIT Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year EBIT Growth's Fluicell historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Fluicell

All Key Metrics — Fluicell